Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

NCT03836716 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
120
Enrollment
INDUSTRY
Sponsor class

Stopped As a consequence of the results of ORARIALS-01 which did not meet any of its efficacy endpoints. The planned duration was 152 weeks. After termination, the actual mean duration of treatment was approx. 28 weeks (range approx. 2 to 71 weeks).

Conditions

Interventions

Sponsor

ZevraDenmark